13165-32-7

Upstream product

• 553-27-5 aniline mustard 
• 13165-33-8 1-bromo-4-benzene 
• 1422986-56-8 C₁₂H₁₈BrNO₆S₂ 
• 106-40-1 4-bromo-aniline 

Downstream Products

• 200808-34-0 10-(4-Bromo-phenyl)-1,4,7-trithia-10-aza-cyclododecane 
• 1422986-68-2 4-(bis(2-chloroethyl)amino)phenylboronic acid 
• 1204-69-9 4-[bis(2-chloroethyl)amino]phenol 

Relevant academic research and scientific papers

Twofold photoswitching of NIR fluorescence and EPR based on the PMI-N-HABI for optical nanoimaging of electrospun polymer nanowires

In this article, we report the design and synthesis of a fluorescent molecular switch based on perylenemonoimide-hexaarylbiimidazole dyad (PMI-N-HABI), which exhibits not only photoswitchable near-infrared (NIR) fluorescence but also photoswitchable elect

Reactive oxygen species (ROS) inducible DNA cross-linking agents and their effect on cancer cells and normal lymphocytes

Reducing host toxicity is one of the main challenges of cancer chemotherapy. Many tumor cells contain high levels of ROS that make them distinctively different from normal cells. We report a series of ROS-activated aromatic nitrogen mustards that selectively kill chronic lymphocytic leukemia (CLL) over normal lymphocytes. These agents showed powerful DNA cross-linking abilities when coupled with H2O2, one of the most common ROS in cancer cells, whereas little DNA cross-linking was detected without H2O2. Consistent with chemistry observation, in vitro cytotoxicity assay demonstrated that these agents induced 40-80% apoptosis in primary leukemic lymphocytes isolated from CLL patients but less than 25% cell death to normal lymphocytes from healthy donors. The IC50 for the most potent compound (2) was ～5 μM in CLL cells, while the IC 50 was not achieved in normal lymphocytes. Collectively, these data provide utility and selectivity of these agents that will inspire further and effective applications.

ANTI-CANCER AGENTS

Described herein are compounds that may be selectively activated to produce active anti-cancer agents in tumor cells. Also disclosed are pharmaceutical compositions comprising the compounds, and methods of treating cancer using the compounds.

4′ Diphenylphosphino and bromo derivatives of 10-phenyl-1,4,7-trithia-10-azacyclododecane 4-R-C6H4N(CH2CH2S) 2CH2CH2SCH2CH2

4-Br-C6H4N(CH2CH2S) 2CH2CH2SCH2CH2 and 4-Ph2P-C6H4N(CH2CH 2S)2CH2CH2SCH2CH 2 have been synthesized and characterized. The former cyclododcane has been obtained from the reaction between 4-BrC6H4N(CH2CH2Cl)2 and S(CH2CH2SH)2 in N,N-dimethylformamide containing Cs2CO3. The latter has been obtained from the former by way of a low temperature lithium-bromine exchange reaction (butyllithium) that provided the carbanion which was subsequently reacted with chlorodiphenylphosphine. In regard to characterization, X-ray methods have been used to study the former (P21 a = 8.356(3) A, b = 12.325(5) A, c = 16.012 (7), β = 100.81, Z = 4), and two crystallographically independent molecules were found. In both molecules, the nitrogen atoms are nearly planar with short N-C(Sp2) bond lengths, and, second, the sulfur atoms are in exodenate positions. For the phosphine, a 31P signal was observed at -7.1 ppm, and this peak position was considered to be indicative of a structure involving a planar nitrogen atom.